A Long-awaited Breakthrough?
Olga Astapova
Endocrinology, Volume 166, Issue 9, September 2025, bqaf111
https://doi.org/10.1210/endocr/bqaf111
In a recently published article from the University of Mississippi titled “Androgen Receptor PROTAC ARV-110 Ameliorates Metabolic Complications in a Mouse Model of Polycystic Ovary Syndrome,” Basnet et al describe the effects of a novel antiandrogen, a proteasome-targeting chimera specific to androgen receptor (AR), in a mouse model of polycystic ovary syndrome (PCOS). They find that this compound, ARV-110, effectively depletes AR in adipose tissue and results in reduced adiposity and improvements in metabolic complications of DHT-induced PCOS — namely, excess weight, glucose tolerance, and circulating lipids. While these effects occurred to some extent in control mice, they are most prominent in the PCOS model, suggesting that they are disease specific. Dose-dependent hepatotoxicity was also reported, partially limiting the use of this drug.
We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.
Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.
